FindTrial
Sign In

A comparative study of propofol- Dexmedetomidine versus propofol-ketamine for anesthetic management of patients during Endoscopic Retrograde Cholangiopancreatography (ERCP)

A Comparative Study of Propofol-Dexmedetomedine versus Propofol- Ketamine for Anesthetic Management of Patients during Endoscopic Retrograde Cholangiopancreatography (ERCP)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052890
Enrollment
50
Registered
2023-05-18
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Intravenous Dexmedetomidine Propofol: Loading dose -Intravenous dexmedetomidine 1 mcg/kg bolus over 10 minutes and propofol 2mg/kg iv Maintenance dose -infusion dexmedetomidine intraven

Sponsors

Dr Ipshita Garg
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Asa 2 and Asa 3 fit patients . Patients that are haemodynamically stable and giving written informed consent.

Exclusion criteria

Exclusion criteria: Procedures less than 20 minutes. Patients refusal . Patients with pre existing cardiovascular diseases. Patients with h/o allergy to test drugs . Patients with neurological disorders and muscle diseases.

Design outcomes

Primary

MeasureTime frame
Comparison of haemodynamic Stability between Propofol Dexmedetomidine and Propofol Ketamine during ERCP Procedures.Timepoint: Baseline BP. BP Every 5 min of loading dose for 15 minutes. At intubation, then every 10 minutes for entire duration of procedure,at extubation. Then post operatively every 15 minutes for an hour.—

Secondary

MeasureTime frame
Post op assessment of Vas score sedation score , Vitals and total propofol consumption at the end of the procedure.Timepoint: Every 15 minutes for 1 hour.—

Countries

India

Contacts

Public ContactDr Ipshita Garg

DR D Y PATIL MEDICAL COLLEGE PUNE

shahbazhsnn@gmail.com9764621253

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026